Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Ibexx who wrote (6719)	1/16/1999 8:43:00 AM
From: Anthony Wong	Read Replies (2) \| Respond to of 9523

Ibexx & thread, this a post re. a research paper "How Super Are The "Super Aspirins"? -- New COX-2 Inhibitors May Elevate Cardiovascular Risk", copied from the MTC thread (the research was funded by G.D. Gearle): To: Anthony Wong (903 ) From: James Nickel Saturday, Jan 16 1999 7:01AM ET Reply #904 of 907 It sounds like Dan may be referring to this paper/release: eurekalert.org:80/releases/upmc-ssa011399.html cited on the Yahoo MTC thread. If you poke around the eurekalert site there is a reference that the study was published/included in the proceedings of the National Academy of Sciences. I did a search over at the NAS cite over the most recent publication and did come up with: pnas.org Same author, same subject area...published on the 5th of Jan. The two papers do not seem consistent to me. Specifically, from the end of the abstract, "There was no significant difference between the doses of celecoxib on COX-2 inhibition. Celecoxib and ibuprofen suppressed urinary excretion of the prostacyclin metabolite 2,3 dinor 6-keto PGF1. These data suggest that (i) platelet COX-1-dependent aggregation is not inhibited by up to 800 mg of celecoxib;(ii) comparable COX-2 inhibition is attained by celecoxib (100-800 mg) and ibuprofen (800 mg) after acute dosing; and (iii) COX-2 is a major source of systemic prostacyclin biosynthesis in healthy humans." But I'll have to admit that in this later paper (abstract) I would like to turn to someone with pharmacological expertise for their opinion. Best Regards, Jim